Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers
Executive Summary
Trial lawyers should work with FDA to focus product liability actions on cases where manufacturers appear to be withholding information, Commissioner McClellan suggested during the National Community Pharmacists Association legislative conference May 19 in Washington, D.C
You may also be interested in...
Pregnancy Adverse Events Could Be Shown Separately Under Labeling Reform
Pregnancy-related labeling reforms could include displaying birth defect incidence information in a separate section from general adverse events, Center for Drug Evaluation & Research Office of New Drugs Pregnancy Labeling Team Leader Kathleen Uhl, MD, suggested
Pregnancy Adverse Events Could Be Shown Separately Under Labeling Reform
Pregnancy-related labeling reforms could include displaying birth defect incidence information in a separate section from general adverse events, Center for Drug Evaluation & Research Office of New Drugs Pregnancy Labeling Team Leader Kathleen Uhl, MD, suggested
Product Liability Litigation Impeding R&D, FDA Commissioner Says
Pharmaceutical research and development is suffering because of the high cost of product liability litigation, FDA Commissioner McClellan said at a U.S. Chamber of Commerce conference in Washington, D.C. July 15